BACKGROUND AND OBJECTIVES: Prior reports have suggested that patients with impaired renal function receive less aggressive care after an acute coronary syndrome (ACS). The aim of this study was to determine whether this held true in a contemporary cohort, after thorough adjustment for cotreatments/comorbidities. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients who were admitted for an ACS in eight participating hospitals were stratified into three groups according to estimated creatinine clearance (CrC): less than 45 ml/min, 45 to 60 ml/min, and reference >60 ml/min. RESULTS: During hospitalization, uses of reperfusion therapy in tertiary care centers [difference between CrC < or =45 ml/min and reference group (Delta): 4%, 95% confidence interval (CI): (-13%, 21%)] and systemic anticoagulation [Delta: 0%, CI (-5%, 5%)] were similar in the three groups. Coronary angiography was performed less often in patients with lower CrC [Delta: -16%, CI: (-31%, -1%)]. At discharge, nearly all patients received either an antiplatelet agent or warfarin regardless of CrC [Delta: -1%, CI: (-3%, 1%)]. Discharge use of angiotensin converting enzyme (ACE) inhibitors or angiotensin-receptor blockers was comparable [Delta: 7%, CI: (-1%, 15%)]. beta-blockers [Delta: -9%, CI: (-17%, -1%)] and lipid-lowering drugs (LLDs) [Delta: -7%, CI: (-13%, -1%)] were used less frequently in patients with lower CrC. In multivariate analyses, decreased CrC predicted lower coronary angiography and LLD use, but not lower beta-blocker use at discharge. CONCLUSIONS: These results suggest that in patients with ACS, the extent of undertreatment due to chronic kidney disease is less than reported previously, which is partially explained by more complete adjustment for cotreatments/comorbidities.
BACKGROUND AND OBJECTIVES: Prior reports have suggested that patients with impaired renal function receive less aggressive care after an acute coronary syndrome (ACS). The aim of this study was to determine whether this held true in a contemporary cohort, after thorough adjustment for cotreatments/comorbidities. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients who were admitted for an ACS in eight participating hospitals were stratified into three groups according to estimated creatinine clearance (CrC): less than 45 ml/min, 45 to 60 ml/min, and reference >60 ml/min. RESULTS: During hospitalization, uses of reperfusion therapy in tertiary care centers [difference between CrC < or =45 ml/min and reference group (Delta): 4%, 95% confidence interval (CI): (-13%, 21%)] and systemic anticoagulation [Delta: 0%, CI (-5%, 5%)] were similar in the three groups. Coronary angiography was performed less often in patients with lower CrC [Delta: -16%, CI: (-31%, -1%)]. At discharge, nearly all patients received either an antiplatelet agent or warfarin regardless of CrC [Delta: -1%, CI: (-3%, 1%)]. Discharge use of angiotensin converting enzyme (ACE) inhibitors or angiotensin-receptor blockers was comparable [Delta: 7%, CI: (-1%, 15%)]. beta-blockers [Delta: -9%, CI: (-17%, -1%)] and lipid-lowering drugs (LLDs) [Delta: -7%, CI: (-13%, -1%)] were used less frequently in patients with lower CrC. In multivariate analyses, decreased CrC predicted lower coronary angiography and LLD use, but not lower beta-blocker use at discharge. CONCLUSIONS: These results suggest that in patients with ACS, the extent of undertreatment due to chronic kidney disease is less than reported previously, which is partially explained by more complete adjustment for cotreatments/comorbidities.
Authors: Andrew T Yan; Raymond T Yan; Mary Tan; Thao Huynh; Kamyar Soghrati; Lawrence J Brunner; Paul DeYoung; David H Fitchett; Anatoly Langer; Shaun G Goodman Journal: Am Heart J Date: 2007-09-14 Impact factor: 4.749
Authors: Alberto Roghi; Stefano Savonitto; Claudio Cavallini; Gustavo Arraiz; Luigi Angoli; Fausto Castriota; Guglielmo Bernardi; Mara Sansa; Stefano De Servi; Walter Pitscheider; Gian Battista Danzi; Bernhard Reimers; Silvio Klugmann; Martina Zaninotto; Diego Ardissino Journal: J Cardiovasc Med (Hagerstown) Date: 2008-04 Impact factor: 2.160
Authors: James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger Journal: J Am Coll Cardiol Date: 2008-04-15 Impact factor: 24.094
Authors: Peter Bogaty; Luce Boyer; Serge Simard; Franz Dauwe; Robert Dupuis; Benoît Verret; Thao Huynh; Fernand Bertrand; Gilles R Dagenais; James M Brophy Journal: J Am Coll Cardiol Date: 2008-06-17 Impact factor: 24.094
Authors: Chiara Melloni; Eric D Peterson; Anita Y Chen; Lynda A Szczech; L Kristin Newby; Robert A Harrington; W Brian Gibler; E Magnus Ohman; Sarah A Spinler; Matthew T Roe; Karen P Alexander Journal: J Am Coll Cardiol Date: 2008-03-11 Impact factor: 24.094
Authors: David H Smith; Eric S Johnson; Denise M Boudreau; Andrea E Cassidy-Bushrow; Stephen P Fortmann; Robert T Greenlee; Jerry H Gurwitz; David J Magid; Catherine J McNeal; Kristi Reynolds; Steven R Steinhubl; Micah Thorp; Jeffrey O Tom; Suma Vupputuri; Jeffrey J VanWormer; Jessica Weinstein; Xiuhai Yang; Alan S Go; Stephen Sidney Journal: Am J Med Date: 2015-07-11 Impact factor: 4.965